Category: pSivida Corp.Syndicate content

Analyst says BSX may take CRM lead | Medtech Wall Street news for the week of September 29, 2014

October 2, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Boston Scientific could take CRM lead; Orthofix CFO bails after 6 months amid deepening financial fix; Fourth time's the charm: pSivida, Alimera jump on FDA nod for Iluvien; Echo Therapeutics is on the ropes; Activist investor erupts at Volcano

Analyst: Boston Scientific could take CRM lead

September 25, 2014 by Alexander Soule

Fourth time's the charm: pSivida, Alimera jump on FDA nod for Iluvien

September 29, 2014 by Brad Perriello

Shares of pSivida and Alimera Sciences jump after the FDA approves their Iluvien treatment for diabetic macular edema.

Fourth time's the charm: pSivida, Alimera jump on FDA nod for Iluvien

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MRI Interventions taps Intuitive Surgical's Grillo for CEO | Personnel Moves

September 11, 2014 by Brad Perriello

MRI Interventions taps Intuitive Surgical marketing & business development executive Frank Grillo to be its new CEO.

MRI Interventions taps Intuitive Surgical's Grillo for CEO | Personnel Moves

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

pSivida, Alimera Sciences soar as Iluvien skips ahead to FDA review

December 19, 2013 by Arezu Sarvestani

pSivida's shares spike 35% on news that the company's Iluvien eye drug/device combination will skip ahead to final FDA review, bypassing the advisory panel process.

pSivida soars as copmany skips FDA avisory panel on review path for Iluvien

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

UK regulators OK pSivida's Iluvien

December 4, 2013 by Chris Walker

The UK's National Institute for Health & Care Excellence OK's pSivida's Iluvien drug/device combo for cataract surgery patients with chronic diabetic macular edema.

pSivida's Iluvien backed by UK National Health Service

pSivida (NSDQ:PSDV) said the UK's National Institute for Health & Care Excellence approved its Iluvien drug/device combination.

The approval is for cataract surgery patients who don't respond to standard treatment for diabetic macular edema, according to a press release.

Third time's no charm for pSivida, Alimera as FDA again denies Iluvien eye treatment

October 18, 2013 by Arezu Sarvestani

Wall Street flees from pSivida and licensee Alimera Sciences as the FDA hands down its 3rd rejection for the Iluvien vision repair implant.

Third time's no charm for pSivida as FDA again denies Iluvien eye treatment

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Alimera's Iluvien vision repair implant wins national insurance coverage in France

July 25, 2013 by Sony Salzman

France grants Alimera's Iluvien vision repair implant national insurance coverage, with up to 100% reimbursement for certain patients.

pSivida
Alimera Sciences

The French National Health Authority granted Alimera Sciences (NSDQ:ALIM) national insurance coverage for the Iluvien vision repair implant, the company said this week.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp